^
BIOMARKER:
No biomarker
News
Twitter
Trials
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive
:
A1
Merck (MSD) Press Release - 1d
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive
:
B
Merck (MSD) Press Release - 1d
No biomarker
Prostate Cancer
enzalutamide
Sensitive
:
A1
Astellas Press Release - 3d
No biomarker
Prostate Cancer
apalutamide
Sensitive
:
A1
J Clin Oncol - 1wk
No biomarker
CLL
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 1wk
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 1wk
No biomarker
Urothelial Cancer
nivolumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 1wk
No biomarker
Urothelial Cancer
pembrolizumab
Sensitive
:
A1
NICE - 1wk
No biomarker
RCC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
No biomarker
Cervical Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
No biomarker
Ovarian Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
No biomarker
GBM
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
No biomarker
CRC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
No biomarker
Breast Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
No biomarker
NSCLC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
No biomarker
Peritoneal Cancer
olaparib + bevacizumab
Sensitive
:
A2
NICE - 1wk
No biomarker
Fallopian Tube Cancer
olaparib + bevacizumab
Sensitive
:
A2
NICE - 1wk
No biomarker
Ovarian Cancer
olaparib + bevacizumab
Sensitive
:
A2
NICE - 1wk
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2wk
No biomarker
AML
azacitidine oral
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2wk
No biomarker
AML
venetoclax
Sensitive
:
A1
Roche Press Release - 2wk
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive
:
A1
N Engl J Med - 2wk
No biomarker
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive
:
A1
FDA - 2wk
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive
:
A1
Sanofi Press Release - 2wk
No biomarker
Multiple Myeloma
ALLO-715
Sensitive
:
B
Allogene Therapeutics Press Release - 2wk
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Gastric Cancer
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive
:
A1
ESMO.org - 3wk
No biomarker
Urothelial Cancer
sacituzumab govitecan-hziy
Sensitive
:
A1
FDA - 3wk
No biomarker
Small Cell Lung Cancer
topotecan
Sensitive
:
A1
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive
:
A1
ESMO.org - 3wk
No biomarker
Multiple Myeloma
selinexor
Sensitive
:
A1
NCCN - 3wk
No biomarker
NSCLC
nivolumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3wk
No biomarker
Multiple Myeloma
idecabtagene vicleucel
Sensitive
:
A1
NCCN - 3wk
No biomarker
Urothelial Cancer
toripalimab
Sensitive
:
A1
GlobeNewswire - 3wk
No biomarker
Small Cell Lung Cancer
CAV
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
CML
bosutinib
Sensitive
:
A2
Int J Hematol - 3wk
No biomarker
Small Cell Lung Cancer
cisplatin
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
carboplatin
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
carboplatin + etoposide IV
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
cisplatin + etoposide IV
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
carboplatin + gemcitabine
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
cisplatin + topotecan
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
cisplatin + irinotecan
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Multiple Myeloma
selinexor + pomalidomide
Sensitive
:
A2
NCCN - 3wk
No biomarker
Multiple Myeloma
selinexor + daratumumab
Sensitive
:
A2
NCCN - 3wk
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
NSCLC
ramucirumab
Sensitive
:
A1
No biomarker
NSCLC
durvalumab
Sensitive
:
A1
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
niraparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
niraparib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
NHL
brentuximab vedotin
Sensitive
:
A1
No biomarker
NSCLC
bevacizumab
Sensitive
:
A1
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
SCCHN
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
NSCLC
DP
Sensitive
:
A1
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide intravenous
Sensitive
:
A1
No biomarker
BCC
fluorouracil topical
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our